PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29998574-5 2019 CYP3A4*22 carriers also showed more pronounced platelet inhibition at 24 hours after ticagrelor ingestion than the controls (43% vs. 21%; P = 0.029). Ticagrelor 85-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 33400617-1 2021 This study was to evaluate the effect of resveratrol on the pharmacokinetics of ticagrelor in rats and the metabolism of ticagrelor in human CYP3A4 and liver microsomes. Ticagrelor 121-131 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-147 33400617-4 2021 The vitro experiment was performed to examine the influence of resveratrol on ticagrelor metabolism in CYP3A4*1, human, and rat liver microsomes. Ticagrelor 78-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 30580183-2 2019 Concomitant treatment with ticagrelor, a moderate CYP3A4 inhibitor, and CYP3A4-metabolized statins such as atorvastatin, might lead to an increased risk of muscle-related adverse events. Ticagrelor 27-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 29412111-9 2019 Ticagrelor is metabolized mainly by CYP3A4, which does not show functionally relevant genetic variability. Ticagrelor 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 25935875-12 2015 CONCLUSION: In patients with ACS, ticagrelor pharmacokinetics is influenced by three genetic loci (SLCO1B1, UGT2B7, and CYP3A4). Ticagrelor 34-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 29167415-2 2017 Yet combined therapeutic regimens have the potential of pharmacological interaction with both ticagrelor and simvastatin being metabolized by CYP3A4. Ticagrelor 94-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 142-148 28049954-3 2017 Three genetic loci (SLCO1B1, CYP3A4, and UGT2B7) were reported to affect ticagrelor pharmacokinetics. Ticagrelor 73-83 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 27563870-4 2016 Moreover, ticagrelor is a cytochrome P450 3A4 substrate/inhibitor and, therefore, caution should be exercised when it is used concomitantly with strong CYP3A4 inducers/inhibitors. Ticagrelor 10-20 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 152-158 28408884-0 2017 Effect of CYP3A4*1G and CYP3A5*3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects. Ticagrelor 91-101 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 10-16 28408884-6 2017 Genetic differences in CYP3A4 and CYP3A5 expression in human volunteers and patients might affect the clearance of ticagrelor or AR-C124910XX in vivo resulting in subsequent variable patient response. Ticagrelor 115-125 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 23-29 28408884-7 2017 Thus, this study is designed to explore the effects of CYP3A4*1G and CYP3A5*3 polymorphisms on the pharmacokinetics and pharmcodynamics of ticagrelor in healthy Chinese subjects. Ticagrelor 139-149 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 28408884-8 2017 The results indicated that the CYP3A4*1G polymorphism significantly influenced the pharmacokinetics of AR-C124910XX, and it may be more important than CYP3A5*3 with respect to influencing ticagrelor pharmacokinetics by increasing CYP3A4 activity. Ticagrelor 188-198 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-37 28408884-8 2017 The results indicated that the CYP3A4*1G polymorphism significantly influenced the pharmacokinetics of AR-C124910XX, and it may be more important than CYP3A5*3 with respect to influencing ticagrelor pharmacokinetics by increasing CYP3A4 activity. Ticagrelor 188-198 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 230-236 23870610-1 2013 BACKGROUND: In vitro studies have demonstrated that ticagrelor, an oral antiplatelet agent, is a substrate, activator, and inhibitor of cytochrome P450 (CYP) 3A. Ticagrelor 52-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 136-160 24477376-7 2014 Ticagrelor is a recently approved P2Y12 receptor antagonist that is subject to drug-drug interactions involving the hepatic cytochrome P450-3A4 enzyme system because of its metabolic elimination pathway. Ticagrelor 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 124-143 24477376-8 2014 This case demonstrates ticagrelor"s drug-drug interaction with phenytoin through a platelet aggregation study and supports the manufacturer recommendation to avoid the combination of ticagrelor with any known inducers of cytochrome P450-3A4 metabolism. Ticagrelor 23-33 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 221-240 23407140-9 2013 However, this benefit may in part be driven by an increased efficacy of CYP3A4-metabolized statins on top of ticagrelor and/or from the inappropriate dose restriction of simvastatin and lovastatin in the clopidogrel arm. Ticagrelor 109-119 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 72-78 23093043-9 2013 Co-administration of strong CYP3A/P-glycoprotein inducers with ticagrelor should be discouraged. Ticagrelor 63-73 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-33 34283374-2 2021 Ticagrelor is metabolized mainly by CYP3A4 and produces a rapid blood concentration-dependent platelet inhibitory effect. Ticagrelor 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42